{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T21:42:26Z","timestamp":1743975746462},"reference-count":69,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2003,8,11]],"date-time":"2003-08-11T00:00:00Z","timestamp":1060560000000},"content-version":"vor","delay-in-days":41,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Deutsche Derma Gesell"],"published-print":{"date-parts":[[2003,7]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p> <jats:italic>Hintergrund:<\/jats:italic> Zu den wichtigsten Faktoren, die zur Pathogenese der Akne beitragen, geh\u00f6rt eine erh\u00f6hte Talgdr\u00fcsenaktivit\u00e4t mit Seborrhoe. Die antiandrogene Therapie zielt auf die androgenmetabolisierenden follikul\u00e4ren Keratinozyten und die Talgdr\u00fcse mit prim\u00e4rer sebostatischer Wirkung, wobei eine Minderung der Talgsyntheserate von 12,5\u2003% bis zu 65\u2003% erreicht werden kann. Nach ihrem Mechanismus teilt man die Antiandrogene ein in Androgenrezeptorblocker sowie Hemmer der zirkulierenden Androgene durch Wirkung auf das Ovar (orale Kontrazeptiva), Hemmer der zirkulierenden Androgene durch Wirkung auf die Hypophyse (Gonadotropin\u2010releasing\u2010Hormone\u2010Agonisten und Dopamin\u2010Agonisten bei Hyperprolaktin\u00e4mie), Hemmer der Nebennierenrindenaktivit\u00e4t und Hemmer des peripheren Androgenmetabolismus (5\u03b1\u2010Reduktase\u2010Inhibitoren, Hemmer anderer Enzyme).<\/jats:p><jats:p> <jats:italic>Methoden:<\/jats:italic> In dieser Studie wurden alle in MedLine publizierten Original\u2010 und \u00dcbersichtsarbeiten \u00fcber die Therapie der Akne mit Antiandrogenen sowohl als Monotherapie als auch in Kombination mit Hilfe der Suchbegriffe \u201eacne\u201d, \u201eseborrhea\u201d, \u201epolycystic ovary syndrome\u201d, \u201ehyperandrog*\u201d und \u201etreatment\u201d ausgesucht und nach ihrer Evidenzebene eingeteilt.<\/jats:p><jats:p> <jats:italic>Ergebnisse:<\/jats:italic> Von den zur Verf\u00fcgung stehenden therapeutischen M\u00f6glichkeiten zeigen die Kombinationen Cyproteronacetat (2\u2005mg)\/Ethinylestradiol (35\u2005\u00b5g), Drospirenon (3\u2005mg)\/Ethinylestradiol (30\u2005\u00b5g) und das kombiphasische Pr\u00e4parat mit Desogestrel (25\u2005\u00b5g)\/Ethinylestradiol (40\u2005\u00b5g) f\u00fcr 1\u2005Woche gefolgt von Desogestrel (125\u2005\u00b5g)\/Ethinylestradiol (30\u2005\u00b5g) f\u00fcr 2\u2005Wochen die st\u00e4rkste Antiakne\u2010Wirkung. Gestagene oder \u00d6strogene jeweils als Monotherapie, Spironolacton, Flutamid, Gonadotropin\u2010Releasing\u2010Hormone\u2010Antagonisten und Hemmer des peripheren Androgenmetabolismus werden nach dem heutigen Kenntnisstand nicht empfohlen. Niedrig dosiertes Prednisolon wird nur bei late\u2010onset kongenitaler adrenaler Hyperplasie eingesetzt und Dopamin\u2010Agonisten nur bei Hyperprolaktin\u00e4mie. Die Therapie mit Antiandrogenen setzt voraus, da\u00df keine entsprechenden Kontraindikationen vorliegen.<\/jats:p><jats:p> <jats:italic>Schlu\u00dffolgerung:<\/jats:italic> Die antiandrogene Therapie ist weiblichen Patienten vorbehalten, die weitere Zeichen eines peripheren Hyperandrogenismus oder einer Hyperandrogen\u00e4mie aufweisen. Zudem k\u00f6nnen Frauen mit Acne tarda oder persistierender therapieresistenter Akne mit gleichzeitigem Kontrazeptionswunsch mit Antiandrogenen behandelt werden sowie im Rahmen der Durchf\u00fchrung einer systemischen Isotretinoin\u2010Therapie. Die antiandrogene Therapie ist keine prim\u00e4re Monotherapie einer nicht entz\u00fcndichen und milden entz\u00fcndlichen Akne.<\/jats:p>","DOI":"10.1046\/j.1610-0387.2003.03011.x","type":"journal-article","created":{"date-parts":[[2003,8,11]],"date-time":"2003-08-11T09:18:51Z","timestamp":1060593531000},"page":"535-546","source":"Crossref","is-referenced-by-count":30,"title":["Therapie der Akne mit Antiandrogenen \u2013 Eine evidenzbasierte \u00dcbersicht"],"prefix":"10.1111","volume":"1","author":[{"given":"Christos C.","family":"Zouboulis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2003,8,11]]},"reference":[{"key":"e_1_2_22_2_2","first-page":"6","article-title":"Acne: Current aspects on pathology and treatment","volume":"1","author":"Zouboulis ChC","year":"1999","journal-title":"Dermatol Experiences"},{"key":"e_1_2_22_3_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2000.110901"},{"key":"e_1_2_22_4_2","doi-asserted-by":"publisher","DOI":"10.1159\/000051771"},{"key":"e_1_2_22_5_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-0960.2001.00489.x"},{"key":"e_1_2_22_6_2","first-page":"59","volume-title":"Neonatal Skin \u2013 Structure and Function. 2. Auflage","author":"Zouboulis ChC","year":"2003"},{"key":"e_1_2_22_7_2","doi-asserted-by":"publisher","DOI":"10.1159\/000053265"},{"key":"e_1_2_22_8_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.2001.01312.x"},{"key":"e_1_2_22_9_2","doi-asserted-by":"publisher","DOI":"10.1159\/000017864"},{"key":"e_1_2_22_10_2","unstructured":"ChenW YangC\u2010C SheuH\u2010M SeltmannH ZouboulisChC. Expression of PPAR and c\/EBP transcription factors in cultured human sebocytes. J Invest Dermatol in press."},{"key":"e_1_2_22_11_2","doi-asserted-by":"publisher","DOI":"10.1159\/000067823"},{"key":"e_1_2_22_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12616181"},{"key":"e_1_2_22_13_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.3.7.865"},{"key":"e_1_2_22_14_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.2002.00613.x"},{"key":"e_1_2_22_15_2","doi-asserted-by":"publisher","DOI":"10.1159\/000053267"},{"key":"e_1_2_22_16_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2002.120912"},{"key":"e_1_2_22_17_2","unstructured":"SackettDL StrausSE RichardsonWS RosenbergW HaynesRB. Evidence\u2010based medicine. How to practice and teach EBM. 2. Auflage Churchill Livingstone London 2001; 169\u200a\u2013\u200a182."},{"key":"e_1_2_22_18_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200363050-00003"},{"key":"e_1_2_22_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1986.tb04880.x"},{"key":"e_1_2_22_20_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2008-1035954"},{"key":"e_1_2_22_21_2","first-page":"697","article-title":"Multicentric clinical trial of a combination of 35 micrograms of ethinylestradiol and 2 mg of cyproterone acetate","volume":"86","author":"Audebert A","year":"1991","journal-title":"Rev Fr Gynecol Obstet"},{"key":"e_1_2_22_22_2","first-page":"157","article-title":"The effectiveness of oral cyproterone acetate in combination with ethinylestradiol in acne tarda of the facial type","volume":"60","author":"Gollnick H","year":"1999","journal-title":"Ann Endocrinol (Paris)"},{"key":"e_1_2_22_23_2","doi-asserted-by":"publisher","DOI":"10.1080\/ejc.6.1.46.53"},{"key":"e_1_2_22_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/16.1.36"},{"key":"e_1_2_22_25_2","doi-asserted-by":"publisher","DOI":"10.3109\/00016348609157049"},{"key":"e_1_2_22_26_2","doi-asserted-by":"publisher","DOI":"10.3109\/00016349009021041"},{"key":"e_1_2_22_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1988.tb01756.x"},{"key":"e_1_2_22_28_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.291.6504.1231"},{"key":"e_1_2_22_29_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2008-1036324"},{"key":"e_1_2_22_30_2","doi-asserted-by":"publisher","DOI":"10.1159\/000051701"},{"key":"e_1_2_22_31_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199856050-00007"},{"key":"e_1_2_22_32_2","first-page":"CD000","article-title":"Spironolactone versus placebo or in combination with steroids for hirsutism and\/or acne","volume":"3","author":"Farquhar C","year":"2001","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_22_33_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2000.105557"},{"key":"e_1_2_22_34_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.2002.01594.x"},{"key":"e_1_2_22_35_2","doi-asserted-by":"publisher","DOI":"10.1177\/106002809502907-817"},{"key":"e_1_2_22_36_2","first-page":"445","article-title":"The relevance of the pharmacologic properties of a progestational agent to its clinical effects as a combination oral contraceptive","volume":"62","author":"Upton GV","year":"1989","journal-title":"Yale J Biol Med"},{"key":"e_1_2_22_37_2","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2340\/0001555564517523","article-title":"Serum total and unbound testosterone and sex hormone binding globulin (SHBG) in female acne patients treated with two different oral contraceptives","volume":"64","author":"Palatsi R","year":"1984","journal-title":"Acta Derm Venereol"},{"key":"e_1_2_22_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0015-0282(01)01938-0"},{"key":"e_1_2_22_39_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-71-1-8"},{"key":"e_1_2_22_40_2","first-page":"647","article-title":"Norgestimate. From the laboratory to three clinical indications","volume":"46","author":"Henzl MR","year":"2001","journal-title":"J Reprod Med"},{"key":"e_1_2_22_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0029-7844(97)00059-8"},{"key":"e_1_2_22_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(97)70112-9"},{"key":"e_1_2_22_43_2","doi-asserted-by":"crossref","unstructured":"SatorP\u2010G SchmidtJB H\u00f6nigsmannH. Clinical evidence of the endocrinological influence of a triphasic oral contraceptive containing norgestimate and ethinyl estradiol in treating women with acne vulgaris.2003;206:241\u200a\u2013\u200a248.","DOI":"10.1159\/000068893"},{"key":"e_1_2_22_44_2","first-page":"2","article-title":"The effect of 2 combined oral contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea","volume":"69","author":"Van Vloten WA","year":"2002","journal-title":"Cutis"},{"key":"e_1_2_22_45_2","doi-asserted-by":"publisher","DOI":"10.1080\/13625180008500411"},{"key":"e_1_2_22_46_2","doi-asserted-by":"publisher","DOI":"10.1080\/713604210"},{"key":"e_1_2_22_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/0010-7824(94)90024-8"},{"key":"e_1_2_22_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0010-7824(99)00109-2"},{"key":"e_1_2_22_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/0010-7824(96)00005-4"},{"key":"e_1_2_22_50_2","first-page":"423","article-title":"Effects on acne of two oral contraceptives containing desogestrel and cyproterone acetate","volume":"41","author":"Charoenvisal C","year":"1996","journal-title":"Int J Fertil Menopausal Stud"},{"key":"e_1_2_22_51_2","doi-asserted-by":"publisher","DOI":"10.1080\/13625180008500405"},{"key":"e_1_2_22_52_2","doi-asserted-by":"publisher","DOI":"10.1053\/cjwh.2001.25638"},{"key":"e_1_2_22_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0010-7824(99)00093-1"},{"key":"e_1_2_22_54_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200124040-00004"},{"key":"e_1_2_22_55_2","first-page":"678","article-title":"Androgen suppression and clinical improvement with dopamine agonists in hyperandrogenic\u2010hyperprolactinemic women","volume":"46","author":"Hagag P","year":"2001","journal-title":"J Reprod Med"},{"key":"e_1_2_22_56_2","doi-asserted-by":"publisher","DOI":"10.1159\/000067821"},{"key":"e_1_2_22_57_2","first-page":"473","article-title":"Behandlung der Acne fulminans mit Isotretinoin und Prednisolon","volume":"76","author":"Bass D","year":"2001","journal-title":"Z Hautkr"},{"key":"e_1_2_22_58_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1999.02982.x"},{"key":"e_1_2_22_59_2","doi-asserted-by":"publisher","DOI":"10.3109\/09513590009167685"},{"key":"e_1_2_22_60_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF03343844"},{"key":"e_1_2_22_61_2","doi-asserted-by":"publisher","DOI":"10.1159\/000211481"},{"key":"e_1_2_22_62_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0968-0896(98)00260-0"},{"key":"e_1_2_22_63_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0968-0896(01)00182-1"},{"key":"e_1_2_22_64_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.134.4.459"},{"key":"e_1_2_22_65_2","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1001\/archderm.1992.01680190053005","article-title":"Inocoterone and acne. The effect of a topical antiandrogen: results of a multicenter clinical trial","volume":"128","author":"Lookingbill DP","year":"1992","journal-title":"Arch Dermatol"},{"key":"e_1_2_22_66_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.1996.tb04006.x"},{"key":"e_1_2_22_67_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.1998.tb10235.x"},{"key":"e_1_2_22_68_2","doi-asserted-by":"publisher","DOI":"10.1016\/0029-7844(95)00022-J"},{"key":"e_1_2_22_69_2","unstructured":"Garcia Cortes M Andrade RJ Lucena MI Sanchez Martinez H Fernandez MC Ferrer T Martin\u2010Vivaldi R Pelaez G Suarez F Rosemary\u2010Gomez M Montero JL Fraga E Camargo R Alcantara R Pizarro MA Garcia\u2010Ruiz E. Flutamide\u2010induced hepatotoxicity: Report of a case series. Rev Esp Enferm Dig 2001; 93: 423\u200a\u2013\u200a432."},{"key":"e_1_2_22_70_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.17.2232"}],"container-title":["JDDG: Journal der Deutschen Dermatologischen Gesellschaft"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1610-0387.2003.03011.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1610-0387.2003.03011.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T12:55:02Z","timestamp":1697201702000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1610-0387.2003.03011.x"}},"subtitle":["Treatment of acne with antiandrogens \u2013 an evidence\u2010based review"],"short-title":[],"issued":{"date-parts":[[2003,7]]},"references-count":69,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2003,7]]}},"alternative-id":["10.1046\/j.1610-0387.2003.03011.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1610-0387.2003.03011.x","archive":["Portico"],"relation":{},"ISSN":["1610-0379","1610-0387"],"issn-type":[{"value":"1610-0379","type":"print"},{"value":"1610-0387","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,7]]}}}